{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:39:00Z","timestamp":1785159540911,"version":"3.55.0"},"reference-count":8,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>\n                    Purpose: Tamsulosin is formulated as sustained release beads within a capsule to prevent rapid absorption and associated hypotension. The package insert advises the capsule is swallowed whole; not crushed, chewed, or opened. To our knowledge, there are no current data on opening capsules for adults with enteral tube feeds. Given the unidentified safety and efficacy of administration via enteral tubes, alternative alpha blockers with less selectivity for alpha\n                    <jats:sub>1A<\/jats:sub>\n                    are often used. Methods: A single center retrospective chart review was conducted at two hospital sites. Adult patients that received at least one dose of tamsulosin or doxazosin while an enteral feeding tube was placed were included. Safety outcomes evaluated were the number of documented tube obstructions and incidence of medication associated hypotension. Results: 169 patients were included. Ten enteral feeding tube obstructions were reported, 4 of 110 (3.64%) in the tamsulosin arm and 6 of 59 (10.17%) in the doxazosin arm (RR .36, 95% CI .11 to 1.22, P = .099). At least 1 episode of medication associated hypotension occurred in 22 of 98 (22.45%) in the tamsulosin arm and 20 of 49 (40.82%) in the doxazosin arm (RR .55, 95% CI .33 to .91, P = .019). Conclusion: There was no statistically significant difference in the number of tube obstructions between patients receiving tamsulosin or doxazosin via enteral tube feeds. Patients receiving doxazosin were at increased risk of experiencing medication related hypotension. Tamsulosin capsules may be opened and administered via enteral feeding tubes if administered with content integrity intact.\n                  <\/jats:p>","DOI":"10.1177\/08971900241233615","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T01:50:35Z","timestamp":1708480235000},"page":"1164-1169","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Feasibility of Opening Tamsulosin Capsules for Enteral Feeding Tube Administration"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2002-8918","authenticated-orcid":false,"given":"Victoria","family":"Fazio","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hackensack Meridian Health JFK University Medical Center, Edison, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Altshuler","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hackensack Meridian Health JFK University Medical Center, Edison, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Bum","family":"Song","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hackensack Meridian Health JFK University Medical Center, Edison, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"bibr1-08971900241233615","volume-title":"Flomax (Tamsulosin) [Prescribing Information]","author":"Boehringer Ingelheim","year":"2009"},{"key":"bibr2-08971900241233615","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.01.091"},{"key":"bibr3-08971900241233615","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03662.x"},{"key":"bibr4-08971900241233615","volume-title":"Cardura (Doxazosin) [Prescribing Information]","author":"Pfizer","year":"2016"},{"key":"bibr5-08971900241233615","volume-title":"Pharmaceutical Pellets Comprising Tamsulosin. Patent US 7018658 B2","author":"Platteeuw J","year":"2006"},{"key":"bibr6-08971900241233615","volume-title":"Oral Dosage Forms that Should not be Crushed","author":"Institute for Safe Medication Practices (ISMP).","year":"2018"},{"issue":"4","key":"bibr7-08971900241233615","first-page":"S3","volume":"8","author":"Lepor H","year":"2006","journal-title":"Rev Urol"},{"key":"bibr8-08971900241233615","doi-asserted-by":"publisher","DOI":"10.1177\/0148607116673053"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241233615","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241233615","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241233615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:22Z","timestamp":1777509502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241233615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/08971900241233615"],"URL":"https:\/\/doi.org\/10.1177\/08971900241233615","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]}}}